P/E ratio for Neurocrine Biosciences (NBIX)
P/E ratio as of April 2024 (TTM): 67.6
According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 67.6225. At the end of 2022 the company had a P/E ratio of 74.2.
P/E ratio history for Neurocrine Biosciences from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 74.2 | -17.25% |
| 2021 | 89.7 | 307.81% |
| 2020 | 22.0 | -91.82% |
| 2019 | 269 | -17.21% |
| 2018 | 325 | -781.9% |
| 2017 | -47.6 | 99.26% |
| 2016 | -23.9 | -56.5% |
| 2015 | -54.9 | 101.59% |
| 2014 | -27.2 | 101.27% |
| 2013 | -13.5 | -112.67% |
| 2012 | 107 | 754.86% |
| 2011 | 12.5 | -127.81% |
| 2010 | -44.9 | 2047.92% |
| 2009 | -2.09 | 50.38% |
| 2008 | -1.39 | 67.02% |
| 2007 | -0.8330 | -77.38% |
| 2006 | -3.68 | -96.48% |
| 2005 | -105 | 169.33% |
| 2004 | -38.8 | -33.81% |
| 2003 | -58.6 | 298.16% |
| 2002 | -14.7 | -59.24% |
| 2001 | -36.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | -79.81% | 🇺🇸 USA |
 AbbVie ABBV | 44.7 | -33.84% | 🇺🇸 USA |
 Eli Lilly LLY | 137 | 103.18% | 🇺🇸 USA |
 Repligen
RGEN | 75.1 | 11.13% | 🇺🇸 USA |
 Athersys ATHX | -0.0045 | -100.01% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | -137 | -303.19% | 🇺🇸 USA |
 Palatin Technologies PTN | -0.6385 | -100.94% | 🇺🇸 USA |
 Royalty Pharma RPRX | 50.7 | -25.01% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.